MDS’ Study Shows Vidaza Prolongs Survival In Acute Myeloid Leukemia
The study looked at older patients with a median age of 70. These are patients who have had ‘no truly adequate treatments,’ however the study found that half
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).